Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid

NCT02417103 · Terminated

Last updated 2026-05-28

This clinical trial tests whether the medication liraglutide, a GLP-1 analog, can help reduce weight in patients who are preparing for bariatric surgery due to obesity.

Status Terminated Stopped early and will not restart.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 2 people

Who can join Ages 18–77 · all sexes

Timeline Started 2011-12 · est. completion 2016-12

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT02417103 ↗

Description as written by the study sponsor.

The aim of this study is to investigate the effect of the treatment with the GLP-1 Analogon Liraglutide on the lipid metabolism an inflammation in adipose tissue.

Treatments tested

GLP-1 (Liraglutide) also known as Victoza Drug

GLP-1 Analogon
Placebo also known as PL1 PR1 Drug

Placebo

Main thing measured	weight reduction
Sponsor	Universitätsklinikum Hamburg-Eppendorf
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02417103 ↗